(Total Views: 294)
Posted On: 02/21/2022 10:12:57 AM
Post# of 1418
$1.3B company wants to join the 3CL protease inhibitor club, but they have a long way to go, having just dosed their first one in phase one.
Also I didn't see them having anti-cytokine properties so they might what to check with Pfizer before spending gobs of money or just to down the easier path
Enanta Pharmaceuticals Doses First Subject in a Phase 1 Clinical Study of EDP-235, its Oral 3CL Protease Inhibitor Specifically - February 16, 2022
"This first-in-human Phase 1 study will evaluate the safety, tolerability, and
pharmacokinetics of oral EDP-235 in single ascending doses (SAD), including a
two-part food effect cohort, and multiple ascending doses (MAD) compared to
placebo in healthy volunteers. All SAD and MAD cohorts will enroll eight
participants who will be randomized to receive EDP-235 or placebo in a 3:1
ratio."
https://www.bloomberg.com/press-releases/2022...ecifically
Also I didn't see them having anti-cytokine properties so they might what to check with Pfizer before spending gobs of money or just to down the easier path
Enanta Pharmaceuticals Doses First Subject in a Phase 1 Clinical Study of EDP-235, its Oral 3CL Protease Inhibitor Specifically - February 16, 2022
"This first-in-human Phase 1 study will evaluate the safety, tolerability, and
pharmacokinetics of oral EDP-235 in single ascending doses (SAD), including a
two-part food effect cohort, and multiple ascending doses (MAD) compared to
placebo in healthy volunteers. All SAD and MAD cohorts will enroll eight
participants who will be randomized to receive EDP-235 or placebo in a 3:1
ratio."
https://www.bloomberg.com/press-releases/2022...ecifically
(1)
(0)Scroll down for more posts ▼
